OTCBB:MCET

Multicell Technologies Stock Signals

> Biotechnology

Buy MCET

*Your capital is at risk

$0.000001

+0 (+0%)

At Close: Jun 03, 2026

Latest Data & Signals Issued

Below are some of the latest signals issued for MultiCell Technologies, Inc.

General

	Signal Type	Signal Value	Data
	Score	0.000	10 days ( 0 %
	Last Price	$0.000001	0 %
Performance History 7 Days $0.000001 $0.000001 0% 30 Days $0.000001 $0.000001 0% 12 Mos $0.00001 $0.000001 -90.00%

3/18

Active Buy Signals

Premium Feature

Specific Signals

Short Term

Net score: 5.41

Signal Type	Signal Value	Importance	Data
High / Low	N/A	Very Low	$0.000001 - $0.000001
Trend - 3 mos	-90.52 %	High	Width: 116.43 %
Pred. range - 3 mos	N/A - $0.00000009871582	Low	-100.00 % - -90.13 %
Volume Direction	Sell	High	Volume: 5,309 · Direction: 0
Pivot Short	Buy	Very Low	May 18, 2026 - 12 days
RSI Short Pivot Signal	Sell	Very Low	Nov 30, -0001 - N/A days
Short MA 3 mos	Sell	Low	May 15, 2026 - 13 days
Long MA 3 mos	Sell	Medium	May 15, 2026 - 13 days
Short/Long MA 3 mos	Sell	Medium	May 26, 2026 - 7 days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now

Long Term

Net score: 25.59

Signal Type	Signal Value	Importance	Data
Trend - 12 mos	-16.33 %	Very High	Width: 662.67 %
Pred. range - 12 mos	N/A - $0.00007515529620	High	-100.00 % - 7,415.53 %
Short MA 12 mos	Sell	Very High	May 15, 2026 - 13 days
Long MA 12 mos	Buy	Very High	Oct 30, 2025 - 146 days
Short/Long MA 12 mos	Sell	Very High	Nov 21, 2025 - 130 days
Pivot Long	Buy	Low	May 18, 2026 - 12 days
RSI Long Pivot Signal	Sell	Low	Jan 13, 2026 - 96 days
Bollinger	Sell	Medium	Nov 30, -0001 - N/A days
MACD	Sell	High	No Dates Stored For This Signal

Notice: Technical analysis is hidden due to insufficient data.

There can be multiple reasons for our algorithm to not provide conclusion. One of them can be low or no liquidity.

If you think this is not correct, please

ABOUT MULTICELL TECHNOLOGIES, INC.

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therape...

Read Full Profile Here